A. Allepuz

发表

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.

K. Yoo, H. Shimada, C. Zwaan, 2021, Blood advances.

Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.

K. Yoo, H. Shimada, C. Zwaan, 2019, Blood.

Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment

M. Quinlan, Masahiko Sato, P. Aimone, 2021, Journal of clinical pharmacology.

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial

M. Mauro, A. Hochhaus, D. Réa, 2023, Leukemia.

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

H. Matsuoka, K. Kirito, I. Matsumura, 2022, Cancer medicine.

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

S. Voloshin, M. Mauro, N. Chaudhri, 2021 .

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

S. Kapoor, M. Mauro, A. Hochhaus, 2023, Leukemia.

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

S. Kapoor, J. Cortes, M. Mauro, 2021, Blood.

S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE

M. Mauro, A. Hochhaus, N. Chaudhri, 2022, HemaSphere.

Effect of femoral head size on metal-on-HXLPE hip arthroplasty outcome in a combined analysis of six national and regional registries.

L. Havelin, B. Bordini, T. Barber, 2014, The Journal of bone and joint surgery. American volume.